Fluidigm Stock Price, Forecast & Analysis (NASDAQ:FLDM)

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

Fluidigm Co. (NASDAQ:FLDM) issued its earnings results on Tuesday, November, 5th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.01. The medical research company earned $26.50 million during the quarter, compared to analysts' expectations of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The firm's quarterly revenue was down 8.5% compared to the same quarter last year. During the same period last year, the company posted ($0.13) earnings per share. View Fluidigm's Earnings History.

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Fluidigm.

4 brokerages have issued 12-month target prices for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $12.67 in the next year. This suggests a possible upside of 443.6% from the stock's current price. View Analyst Price Targets for Fluidigm.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Media headlines about FLDM stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fluidigm earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Fluidigm.

Fluidigm saw a drop in short interest in October. As of October 31st, there was short interest totalling 1,460,000 shares, a drop of 8.8% from the September 30th total of 1,600,000 shares. Based on an average trading volume of 914,300 shares, the short-interest ratio is presently 1.6 days. Approximately 2.1% of the company's stock are sold short. View Fluidigm's Current Options Chain.

Some companies that are related to Fluidigm include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fluidigm investors own include Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Magnachip Semiconductor (MX), BIOLASE (BIOL), LivePerson (LPSN), Universal Display (OLED), ExOne (XONE), Fate Therapeutics (FATE), Illumina (ILMN) and Karyopharm Therapeutics (KPTI).

Fluidigm's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (5.78%), Cadence Capital Management LLC (0.39%), Perkins Capital Management Inc. (0.33%), Assenagon Asset Management S.A. (0.30%), State of New Jersey Common Pension Fund D (0.30%) and California Public Employees Retirement System (0.18%). Company insiders that own Fluidigm stock include Levin Capital Strategies, LP, Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Institutional Ownership Trends for Fluidigm.

FLDM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., SG Americas Securities LLC, Perkins Capital Management Inc., Cerity Partners LLC and Nisa Investment Advisors LLC. Company insiders that have sold Fluidigm company stock in the last year include Levin Easterly Partners Llc and Nicolas Barthelemy. View Insider Buying and Selling for Fluidigm.

FLDM stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Assenagon Asset Management S.A., Dupont Capital Management Corp, Bailard Inc., California Public Employees Retirement System, Tower Research Capital LLC TRC and Cadence Capital Management LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella and Stephen Christopher Linthwaite. View Insider Buying and Selling for Fluidigm.

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLDM stock can currently be purchased for approximately $2.33.

Fluidigm has a market capitalization of $162.10 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Fluidigm employs 535 workers across the globe.View Additional Information About Fluidigm.

The official website for Fluidigm is http://www.fluidigm.com/.

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]